Aeglea Biotherapeutics
Aeglea BioTherapeutics Inc. - Company Overview
Company Overview ... Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with ...
Aeglea BioTherapeutics Inc. - Press Releases
Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria.
Engineering For New Heights in the Treatment of Inflammatory Bowel Disease.
Aeglea BioTherapeutics Announces Name Change to Spyre ...
Spyre aims to create a next-generation of IBD products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision ...
Aeglea BioTherapeutics - LinkedIn
Aeglea BioTherapeutics | 9887 followers on LinkedIn. With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to ...
Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics
Acquisition of Spyre and concurrent oversubscribed $210 million private investment positions the company to advance a leading inflammatory ...
Aeglea BioTherapeutics Inc. - Financials - Quarterly Results
Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update · The Company continues preclinical development efforts on a ...
Aeglea lays off more staff, seeks exit in face of rocky data
Aeglea BioTherapeutics is letting go of all but 10 employees in another round of layoffs, as the biotech throws in the towel.
Aeglea BioTherapeutics Inc. - Events & Presentations
© 2021 Aeglea BioTherapeutics. Privacy Policy Terms of Use Purchase Terms ... Aeglea BioTherapeutics is now Spyre Therapeutics. View Press Release.
Aeglea Biotherapeutics - HCU Network America
Aeglea BioTherapeutics: Enzyme Replacement Therapy ... Aeglea BioTherapeutics is in the process of developing an enzyme replacement therapy for patients with CBS ...
Aeglea BioTherapeutics Inc. - Resources - Investor FAQs
Where is Aeglea BioTherapeutics' corporate headquarters? Aeglea BioTherapeutics is headquartered at 805 Las Cimas Parkway, Suite 100, Austin, TX 78746.
AEGLEA BIOTHERAPEUTICS - Orphanet
Aeglea BioTherapeutics, 805 Las Cimas Parkway, Suite 100 TX 78746 AUSTIN UNITED STATES, Phone 1: 001(512) 942-2935.
Aeglea BioTherapeutics (@aegleabio) / X
We are thrilled to announce the appointment of Scott Burrows to the role of Chief Financial Officer and Heidy Abreu King-Jones to the role of Chief Legal ...
Aeglea BioTherapeutics company information, funding & investors
Aeglea BioTherapeutics, drugs for the treatment of tumors the company was incorporated in 2013 and is based in texas. Here you'll find information about ...
Aeglea BioTherapeutics - 22 Fillmore
22 Fillmore teamed with Aeglea to fine tune its positioning and brand identity as the company prepares for the potential commercialization of its lead Phase 3 ...
Aeglea BioTherapeutics Announces Sale of Pegzilarginase to ...
Pegzilarginase has been in development for the treatment of people with ARG1-D, a rare debilitating and progressive disease characterized by the ...
Aeglea BioTherapeutics Company Profile 2024 - PitchBook
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products.
Aeglea BioTherapeutics - Crunchbase Company Profile & Funding
Aeglea BioTherapeutics is a clinical-stage biotechnology company that develops enzyme therapies for rare metabolic diseases.
Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics
Aeglea BioTherapeutics, Inc. (Aeglea) (NASDAQ: AGLE), today announced it has completed the acquisition of Spyre Therapeutics, Inc. (Spyre).